nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—Hepatic insufficiency—Methotrexate—esophageal cancer	0.0181	0.045	CcSEcCtD
Atomoxetine—Sinus tachycardia—Capecitabine—esophageal cancer	0.00935	0.0232	CcSEcCtD
Atomoxetine—Depressed mood—Capecitabine—esophageal cancer	0.00842	0.0209	CcSEcCtD
Atomoxetine—Peripheral coldness—Capecitabine—esophageal cancer	0.00791	0.0196	CcSEcCtD
Atomoxetine—Rhinorrhoea—Cisplatin—esophageal cancer	0.00631	0.0157	CcSEcCtD
Atomoxetine—Myoclonus—Capecitabine—esophageal cancer	0.00626	0.0155	CcSEcCtD
Atomoxetine—Infection—Carboplatin—esophageal cancer	0.00617	0.0153	CcSEcCtD
Atomoxetine—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00558	0.0139	CcSEcCtD
Atomoxetine—Laryngeal pain—Capecitabine—esophageal cancer	0.00552	0.0137	CcSEcCtD
Atomoxetine—Pain—Carboplatin—esophageal cancer	0.00531	0.0132	CcSEcCtD
Atomoxetine—Throat sore—Capecitabine—esophageal cancer	0.00522	0.013	CcSEcCtD
Atomoxetine—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00518	0.0129	CcSEcCtD
Atomoxetine—Body temperature increased—Carboplatin—esophageal cancer	0.00491	0.0122	CcSEcCtD
Atomoxetine—Rhinorrhoea—Capecitabine—esophageal cancer	0.00465	0.0115	CcSEcCtD
Atomoxetine—Rigors—Capecitabine—esophageal cancer	0.00461	0.0115	CcSEcCtD
Atomoxetine—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00414	0.0103	CcSEcCtD
Atomoxetine—Nasal congestion—Cisplatin—esophageal cancer	0.00407	0.0101	CcSEcCtD
Atomoxetine—Blood pressure increased—Capecitabine—esophageal cancer	0.00377	0.00935	CcSEcCtD
Atomoxetine—Irritability—Cisplatin—esophageal cancer	0.00354	0.00879	CcSEcCtD
Atomoxetine—Breast disorder—Cisplatin—esophageal cancer	0.00335	0.00832	CcSEcCtD
Atomoxetine—Nasopharyngitis—Cisplatin—esophageal cancer	0.00332	0.00824	CcSEcCtD
Atomoxetine—Sleep disorder—Capecitabine—esophageal cancer	0.00316	0.00784	CcSEcCtD
Atomoxetine—Sweating increased—Cisplatin—esophageal cancer	0.00312	0.00776	CcSEcCtD
Atomoxetine—Bone disorder—Methotrexate—esophageal cancer	0.0031	0.00771	CcSEcCtD
Atomoxetine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00307	0.00763	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS1—esophageal cancer	0.00306	0.134	CrCbGaD
Atomoxetine—Hepatic failure—Capecitabine—esophageal cancer	0.00304	0.00756	CcSEcCtD
Atomoxetine—Libido decreased—Capecitabine—esophageal cancer	0.00295	0.00732	CcSEcCtD
Atomoxetine—Hot flush—Capecitabine—esophageal cancer	0.00292	0.00726	CcSEcCtD
Atomoxetine—Menopausal symptoms—Capecitabine—esophageal cancer	0.0029	0.0072	CcSEcCtD
Atomoxetine—Thirst—Capecitabine—esophageal cancer	0.00287	0.00714	CcSEcCtD
Atomoxetine—Lethargy—Capecitabine—esophageal cancer	0.00279	0.00693	CcSEcCtD
Atomoxetine—Conjunctivitis—Cisplatin—esophageal cancer	0.00278	0.0069	CcSEcCtD
Atomoxetine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00271	0.00674	CcSEcCtD
Atomoxetine—Irritability—Capecitabine—esophageal cancer	0.00261	0.00648	CcSEcCtD
Atomoxetine—Urinary retention—Capecitabine—esophageal cancer	0.0026	0.00646	CcSEcCtD
Atomoxetine—Mood swings—Capecitabine—esophageal cancer	0.00259	0.00643	CcSEcCtD
Atomoxetine—Coma—Methotrexate—esophageal cancer	0.00256	0.00636	CcSEcCtD
Atomoxetine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00253	0.00629	CcSEcCtD
Atomoxetine—Urethral disorder—Cisplatin—esophageal cancer	0.00251	0.00625	CcSEcCtD
Atomoxetine—Abdominal pain upper—Capecitabine—esophageal cancer	0.0025	0.0062	CcSEcCtD
Atomoxetine—Breast disorder—Capecitabine—esophageal cancer	0.00247	0.00614	CcSEcCtD
Atomoxetine—Nasopharyngitis—Capecitabine—esophageal cancer	0.00244	0.00607	CcSEcCtD
Atomoxetine—Flushing—Cisplatin—esophageal cancer	0.00238	0.00591	CcSEcCtD
Atomoxetine—Cardiac disorder—Cisplatin—esophageal cancer	0.00238	0.00591	CcSEcCtD
Atomoxetine—Influenza—Capecitabine—esophageal cancer	0.00236	0.00587	CcSEcCtD
Atomoxetine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00231	0.00574	CcSEcCtD
Atomoxetine—Sweating increased—Capecitabine—esophageal cancer	0.0023	0.00572	CcSEcCtD
Atomoxetine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00226	0.00563	CcSEcCtD
Atomoxetine—Hepatic failure—Methotrexate—esophageal cancer	0.00226	0.00562	CcSEcCtD
Atomoxetine—Malnutrition—Cisplatin—esophageal cancer	0.00223	0.00555	CcSEcCtD
Atomoxetine—Dysuria—Capecitabine—esophageal cancer	0.00221	0.00549	CcSEcCtD
Atomoxetine—Flatulence—Cisplatin—esophageal cancer	0.0022	0.00547	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0022	0.00545	CcSEcCtD
Atomoxetine—Muscle spasms—Cisplatin—esophageal cancer	0.00215	0.00533	CcSEcCtD
Atomoxetine—Weight decreased—Capecitabine—esophageal cancer	0.00214	0.00531	CcSEcCtD
Atomoxetine—Infestation NOS—Capecitabine—esophageal cancer	0.00211	0.00523	CcSEcCtD
Atomoxetine—Infestation—Capecitabine—esophageal cancer	0.00211	0.00523	CcSEcCtD
Atomoxetine—Vision blurred—Cisplatin—esophageal cancer	0.0021	0.00523	CcSEcCtD
Atomoxetine—Depression—Capecitabine—esophageal cancer	0.0021	0.00522	CcSEcCtD
Atomoxetine—Tremor—Cisplatin—esophageal cancer	0.00209	0.0052	CcSEcCtD
Atomoxetine—Lethargy—Methotrexate—esophageal cancer	0.00208	0.00516	CcSEcCtD
Atomoxetine—Conjunctivitis—Capecitabine—esophageal cancer	0.00205	0.00509	CcSEcCtD
Atomoxetine—Reboxetine—ABCB1—esophageal cancer	0.00199	0.087	CrCbGaD
Atomoxetine—Irritability—Methotrexate—esophageal cancer	0.00194	0.00482	CcSEcCtD
Atomoxetine—Convulsion—Cisplatin—esophageal cancer	0.00193	0.00481	CcSEcCtD
Atomoxetine—Mood swings—Methotrexate—esophageal cancer	0.00193	0.00479	CcSEcCtD
Atomoxetine—Myalgia—Cisplatin—esophageal cancer	0.0019	0.00472	CcSEcCtD
Atomoxetine—Anxiety—Cisplatin—esophageal cancer	0.00189	0.00471	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00189	0.00469	CcSEcCtD
Atomoxetine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00188	0.00467	CcSEcCtD
Atomoxetine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00187	0.00464	CcSEcCtD
Atomoxetine—Urethral disorder—Capecitabine—esophageal cancer	0.00185	0.0046	CcSEcCtD
Atomoxetine—Breast disorder—Methotrexate—esophageal cancer	0.00184	0.00457	CcSEcCtD
Atomoxetine—Protriptyline—ABCB1—esophageal cancer	0.00183	0.0799	CrCbGaD
Atomoxetine—Infection—Cisplatin—esophageal cancer	0.00181	0.0045	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS1—esophageal cancer	0.00181	0.079	CrCbGaD
Atomoxetine—Nervous system disorder—Cisplatin—esophageal cancer	0.00179	0.00444	CcSEcCtD
Atomoxetine—Tachycardia—Cisplatin—esophageal cancer	0.00178	0.00442	CcSEcCtD
Atomoxetine—Skin disorder—Cisplatin—esophageal cancer	0.00177	0.0044	CcSEcCtD
Atomoxetine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00176	0.00438	CcSEcCtD
Atomoxetine—Cardiac disorder—Capecitabine—esophageal cancer	0.00176	0.00436	CcSEcCtD
Atomoxetine—Flushing—Capecitabine—esophageal cancer	0.00176	0.00436	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—esophageal cancer	0.00175	0.0765	CrCbGaD
Atomoxetine—Anorexia—Cisplatin—esophageal cancer	0.00174	0.00432	CcSEcCtD
Atomoxetine—Angiopathy—Capecitabine—esophageal cancer	0.00172	0.00426	CcSEcCtD
Atomoxetine—Mediastinal disorder—Capecitabine—esophageal cancer	0.0017	0.00423	CcSEcCtD
Atomoxetine—Chills—Capecitabine—esophageal cancer	0.0017	0.00422	CcSEcCtD
Atomoxetine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00169	0.00419	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00166	0.00412	CcSEcCtD
Atomoxetine—Mental disorder—Capecitabine—esophageal cancer	0.00166	0.00412	CcSEcCtD
Atomoxetine—Malnutrition—Capecitabine—esophageal cancer	0.00165	0.00409	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—esophageal cancer	0.00164	0.00409	CcSEcCtD
Atomoxetine—Paraesthesia—Cisplatin—esophageal cancer	0.00164	0.00407	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00163	0.00406	CcSEcCtD
Atomoxetine—Flatulence—Capecitabine—esophageal cancer	0.00162	0.00403	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00162	0.00402	CcSEcCtD
Atomoxetine—Dysgeusia—Capecitabine—esophageal cancer	0.00161	0.004	CcSEcCtD
Atomoxetine—Methadone—CYP19A1—esophageal cancer	0.0016	0.0699	CrCbGaD
Atomoxetine—Back pain—Capecitabine—esophageal cancer	0.00159	0.00396	CcSEcCtD
Atomoxetine—Decreased appetite—Cisplatin—esophageal cancer	0.00158	0.00394	CcSEcCtD
Atomoxetine—Muscle spasms—Capecitabine—esophageal cancer	0.00158	0.00393	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00157	0.00391	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—esophageal cancer	0.00157	0.0039	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—esophageal cancer	0.00157	0.0039	CcSEcCtD
Atomoxetine—Depression—Methotrexate—esophageal cancer	0.00156	0.00388	CcSEcCtD
Atomoxetine—Pain—Cisplatin—esophageal cancer	0.00156	0.00387	CcSEcCtD
Atomoxetine—Vision blurred—Capecitabine—esophageal cancer	0.00155	0.00385	CcSEcCtD
Atomoxetine—Desipramine—CYP2A6—esophageal cancer	0.00155	0.0677	CrCbGaD
Atomoxetine—Tremor—Capecitabine—esophageal cancer	0.00154	0.00383	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—esophageal cancer	0.00152	0.00379	CcSEcCtD
Atomoxetine—Feeling abnormal—Cisplatin—esophageal cancer	0.0015	0.00373	CcSEcCtD
Atomoxetine—Vertigo—Capecitabine—esophageal cancer	0.00148	0.00367	CcSEcCtD
Atomoxetine—Syncope—Capecitabine—esophageal cancer	0.00148	0.00367	CcSEcCtD
Atomoxetine—Palpitations—Capecitabine—esophageal cancer	0.00145	0.00361	CcSEcCtD
Atomoxetine—Loss of consciousness—Capecitabine—esophageal cancer	0.00145	0.00359	CcSEcCtD
Atomoxetine—Nortriptyline—PTGS1—esophageal cancer	0.00144	0.063	CrCbGaD
Atomoxetine—Body temperature increased—Cisplatin—esophageal cancer	0.00144	0.00358	CcSEcCtD
Atomoxetine—Cough—Capecitabine—esophageal cancer	0.00144	0.00357	CcSEcCtD
Atomoxetine—Arthralgia—Capecitabine—esophageal cancer	0.0014	0.00348	CcSEcCtD
Atomoxetine—Chest pain—Capecitabine—esophageal cancer	0.0014	0.00348	CcSEcCtD
Atomoxetine—Myalgia—Capecitabine—esophageal cancer	0.0014	0.00348	CcSEcCtD
Atomoxetine—Anxiety—Capecitabine—esophageal cancer	0.0014	0.00347	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00139	0.00346	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00139	0.00345	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—esophageal cancer	0.00138	0.00343	CcSEcCtD
Atomoxetine—Dry mouth—Capecitabine—esophageal cancer	0.00137	0.0034	CcSEcCtD
Atomoxetine—Infection—Capecitabine—esophageal cancer	0.00133	0.00332	CcSEcCtD
Atomoxetine—Diphenhydramine—PTGS1—esophageal cancer	0.00133	0.0582	CrCbGaD
Atomoxetine—Shock—Capecitabine—esophageal cancer	0.00132	0.00328	CcSEcCtD
Atomoxetine—Nervous system disorder—Capecitabine—esophageal cancer	0.00132	0.00327	CcSEcCtD
Atomoxetine—Tachycardia—Capecitabine—esophageal cancer	0.00131	0.00326	CcSEcCtD
Atomoxetine—Asthenia—Cisplatin—esophageal cancer	0.00131	0.00325	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—esophageal cancer	0.00131	0.00325	CcSEcCtD
Atomoxetine—Skin disorder—Capecitabine—esophageal cancer	0.0013	0.00324	CcSEcCtD
Atomoxetine—Hyperhidrosis—Capecitabine—esophageal cancer	0.0013	0.00323	CcSEcCtD
Atomoxetine—Anorexia—Capecitabine—esophageal cancer	0.00128	0.00318	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—esophageal cancer	0.00128	0.00317	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00127	0.00315	CcSEcCtD
Atomoxetine—Chills—Methotrexate—esophageal cancer	0.00126	0.00314	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—esophageal cancer	0.00125	0.0545	CrCbGaD
Atomoxetine—Diarrhoea—Cisplatin—esophageal cancer	0.00125	0.0031	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—esophageal cancer	0.00123	0.00306	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—esophageal cancer	0.00123	0.00304	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00122	0.00304	CcSEcCtD
Atomoxetine—Insomnia—Capecitabine—esophageal cancer	0.00122	0.00302	CcSEcCtD
Atomoxetine—Paraesthesia—Capecitabine—esophageal cancer	0.00121	0.003	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—esophageal cancer	0.0012	0.00298	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—esophageal cancer	0.00119	0.00294	CcSEcCtD
Atomoxetine—Dyspepsia—Capecitabine—esophageal cancer	0.00118	0.00294	CcSEcCtD
Atomoxetine—Decreased appetite—Capecitabine—esophageal cancer	0.00117	0.0029	CcSEcCtD
Atomoxetine—Maprotiline—ABCB1—esophageal cancer	0.00117	0.051	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00116	0.00288	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—esophageal cancer	0.00116	0.00288	CcSEcCtD
Atomoxetine—Fatigue—Capecitabine—esophageal cancer	0.00116	0.00288	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—esophageal cancer	0.00115	0.00287	CcSEcCtD
Atomoxetine—Rash—Cisplatin—esophageal cancer	0.00115	0.00285	CcSEcCtD
Atomoxetine—Pain—Capecitabine—esophageal cancer	0.00115	0.00285	CcSEcCtD
Atomoxetine—Constipation—Capecitabine—esophageal cancer	0.00115	0.00285	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—esophageal cancer	0.00115	0.00285	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—esophageal cancer	0.00111	0.0486	CrCbGaD
Atomoxetine—Feeling abnormal—Capecitabine—esophageal cancer	0.00111	0.00275	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—esophageal cancer	0.0011	0.00274	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0011	0.00273	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—esophageal cancer	0.00108	0.00269	CcSEcCtD
Atomoxetine—Cough—Methotrexate—esophageal cancer	0.00107	0.00266	CcSEcCtD
Atomoxetine—Urticaria—Capecitabine—esophageal cancer	0.00107	0.00265	CcSEcCtD
Atomoxetine—Abdominal pain—Capecitabine—esophageal cancer	0.00106	0.00264	CcSEcCtD
Atomoxetine—Body temperature increased—Capecitabine—esophageal cancer	0.00106	0.00264	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—esophageal cancer	0.00106	0.00264	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—esophageal cancer	0.00104	0.00259	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—esophageal cancer	0.00104	0.00259	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—esophageal cancer	0.00104	0.00259	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00104	0.00257	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—esophageal cancer	0.00103	0.0451	CrCbGaD
Atomoxetine—Infection—Methotrexate—esophageal cancer	0.000994	0.00247	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—esophageal cancer	0.000981	0.00244	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—esophageal cancer	0.000971	0.00241	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000967	0.0024	CcSEcCtD
Atomoxetine—Asthenia—Capecitabine—esophageal cancer	0.000964	0.00239	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—esophageal cancer	0.000953	0.00237	CcSEcCtD
Atomoxetine—Pruritus—Capecitabine—esophageal cancer	0.000951	0.00236	CcSEcCtD
Atomoxetine—Diarrhoea—Capecitabine—esophageal cancer	0.000919	0.00228	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000911	0.00226	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—esophageal cancer	0.000905	0.00225	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—esophageal cancer	0.000898	0.00223	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—esophageal cancer	0.000889	0.00221	CcSEcCtD
Atomoxetine—Dizziness—Capecitabine—esophageal cancer	0.000888	0.00221	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—esophageal cancer	0.00088	0.00219	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—esophageal cancer	0.000869	0.00216	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000863	0.00214	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—esophageal cancer	0.000862	0.00214	CcSEcCtD
Atomoxetine—Pain—Methotrexate—esophageal cancer	0.000855	0.00212	CcSEcCtD
Atomoxetine—Vomiting—Capecitabine—esophageal cancer	0.000854	0.00212	CcSEcCtD
Atomoxetine—Rash—Capecitabine—esophageal cancer	0.000847	0.0021	CcSEcCtD
Atomoxetine—Dermatitis—Capecitabine—esophageal cancer	0.000846	0.0021	CcSEcCtD
Atomoxetine—Headache—Capecitabine—esophageal cancer	0.000842	0.00209	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—esophageal cancer	0.000824	0.00205	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000818	0.00203	CcSEcCtD
Atomoxetine—Nausea—Capecitabine—esophageal cancer	0.000798	0.00198	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—esophageal cancer	0.000795	0.00197	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—esophageal cancer	0.000791	0.00196	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—esophageal cancer	0.000791	0.00196	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—esophageal cancer	0.000762	0.0333	CrCbGaD
Atomoxetine—Asthenia—Methotrexate—esophageal cancer	0.000718	0.00178	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—esophageal cancer	0.000708	0.00176	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—esophageal cancer	0.000684	0.0017	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—esophageal cancer	0.000661	0.00164	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—esophageal cancer	0.000636	0.00158	CcSEcCtD
Atomoxetine—Rash—Methotrexate—esophageal cancer	0.000631	0.00157	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—esophageal cancer	0.00063	0.00157	CcSEcCtD
Atomoxetine—Headache—Methotrexate—esophageal cancer	0.000627	0.00156	CcSEcCtD
Atomoxetine—Methadone—ABCB1—esophageal cancer	0.000625	0.0273	CrCbGaD
Atomoxetine—Nausea—Methotrexate—esophageal cancer	0.000594	0.00148	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—esophageal cancer	0.000577	0.0252	CrCbGaD
Atomoxetine—HTR6—Signaling Pathways—ANXA1—esophageal cancer	0.000174	0.000303	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PSME1—esophageal cancer	0.000173	0.000302	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PSME2—esophageal cancer	0.000173	0.000302	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ANXA1—esophageal cancer	0.000173	0.000301	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000172	0.000299	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000172	0.000299	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000172	0.000299	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CA2—esophageal cancer	0.000171	0.000297	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PSME1—esophageal cancer	0.00017	0.000296	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PSME2—esophageal cancer	0.00017	0.000296	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SST—esophageal cancer	0.000169	0.000295	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ANXA1—esophageal cancer	0.000169	0.000294	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SST—esophageal cancer	0.000168	0.000292	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000167	0.000291	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCND1—esophageal cancer	0.000167	0.00029	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000166	0.000289	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GHRL—esophageal cancer	0.000165	0.000287	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH3—esophageal cancer	0.000165	0.000287	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDE4D—esophageal cancer	0.000164	0.000286	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SST—esophageal cancer	0.000164	0.000286	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GHRL—esophageal cancer	0.000164	0.000285	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH3—esophageal cancer	0.000164	0.000285	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FBXW7—esophageal cancer	0.000162	0.000282	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDKN1A—esophageal cancer	0.000161	0.00028	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FBXW7—esophageal cancer	0.000161	0.00028	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH3—esophageal cancer	0.00016	0.000279	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GHRL—esophageal cancer	0.00016	0.000279	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ELMO1—esophageal cancer	0.00016	0.000278	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLCE1—esophageal cancer	0.000159	0.000276	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADH7—esophageal cancer	0.000159	0.000276	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FBXW7—esophageal cancer	0.000158	0.000274	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000157	0.000273	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000157	0.000273	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000156	0.000272	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNG7—esophageal cancer	0.000156	0.000272	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKAP13—esophageal cancer	0.000156	0.000272	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EP300—esophageal cancer	0.000153	0.000267	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH2—esophageal cancer	0.000148	0.000257	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH2—esophageal cancer	0.000147	0.000256	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—XIAP—esophageal cancer	0.000147	0.000255	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000146	0.000254	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000146	0.000254	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000144	0.000251	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH2—esophageal cancer	0.000144	0.00025	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDE4D—esophageal cancer	0.000143	0.000249	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADH1B—esophageal cancer	0.000139	0.000242	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNA1—esophageal cancer	0.000139	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL2—esophageal cancer	0.000138	0.00024	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNG7—esophageal cancer	0.000136	0.000236	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MYC—esophageal cancer	0.000134	0.000232	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMP—esophageal cancer	0.000133	0.000232	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000132	0.00023	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000132	0.00023	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFBR2—esophageal cancer	0.000131	0.000228	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—esophageal cancer	0.000131	0.000227	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFBR2—esophageal cancer	0.00013	0.000227	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP26A1—esophageal cancer	0.000129	0.000225	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PSME2—esophageal cancer	0.000129	0.000224	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PSME1—esophageal cancer	0.000129	0.000224	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ANXA1—esophageal cancer	0.000128	0.000223	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000128	0.000223	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFBR2—esophageal cancer	0.000128	0.000222	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—XIAP—esophageal cancer	0.000127	0.000222	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALOX15—esophageal cancer	0.000126	0.00022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SST—esophageal cancer	0.000125	0.000217	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMAD4—esophageal cancer	0.000124	0.000216	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMAD4—esophageal cancer	0.000123	0.000215	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000122	0.000213	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH3—esophageal cancer	0.000121	0.000211	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GHRL—esophageal cancer	0.000121	0.000211	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMAD4—esophageal cancer	0.000121	0.00021	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNA1—esophageal cancer	0.00012	0.000209	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPI1—esophageal cancer	0.00012	0.000209	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTO1—esophageal cancer	0.00012	0.000209	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL2—esophageal cancer	0.00012	0.000208	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FBXW7—esophageal cancer	0.000119	0.000208	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000119	0.000207	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000116	0.000202	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALDOB—esophageal cancer	0.000115	0.000201	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PIK3CA—esophageal cancer	0.000113	0.000197	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000112	0.000195	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000112	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PSME2—esophageal cancer	0.000112	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PSME1—esophageal cancer	0.000112	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	0.000111	0.000194	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GAPDH—esophageal cancer	0.000111	0.000193	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000111	0.000193	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000111	0.000193	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CRABP1—esophageal cancer	0.00011	0.000192	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—esophageal cancer	0.00011	0.000191	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	0.000109	0.00019	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SST—esophageal cancer	0.000108	0.000188	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000106	0.000185	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GHRL—esophageal cancer	0.000105	0.000184	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	0.000105	0.000184	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNG7—esophageal cancer	0.000105	0.000182	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	0.000104	0.000181	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000103	0.000179	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000102	0.000178	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HIF1A—esophageal cancer	0.000102	0.000177	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000101	0.000176	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	0.000101	0.000176	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	9.88e-05	0.000172	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALDH2—esophageal cancer	9.81e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KDR—esophageal cancer	9.72e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	9.66e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KDR—esophageal cancer	9.65e-05	0.000168	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNG7—esophageal cancer	9.63e-05	0.000168	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADH7—esophageal cancer	9.55e-05	0.000166	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.55e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	9.46e-05	0.000165	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KDR—esophageal cancer	9.45e-05	0.000164	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTT1—esophageal cancer	9.33e-05	0.000162	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	9.23e-05	0.000161	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.19e-05	0.00016	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	9.16e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	9.15e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	9.09e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.02e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	8.9e-05	0.000155	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO1—esophageal cancer	8.75e-05	0.000152	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS1—esophageal cancer	8.75e-05	0.000152	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PSME2—esophageal cancer	8.62e-05	0.00015	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PSME1—esophageal cancer	8.62e-05	0.00015	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—esophageal cancer	8.58e-05	0.000149	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.49e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	8.39e-05	0.000146	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.37e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CREBBP—esophageal cancer	8.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	8.24e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—esophageal cancer	8.16e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	8.1e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	8.07e-05	0.00014	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO1—esophageal cancer	8.04e-05	0.00014	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.04e-05	0.00014	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMP—esophageal cancer	8e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	7.94e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	7.93e-05	0.000138	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSME2—esophageal cancer	7.93e-05	0.000138	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSME1—esophageal cancer	7.93e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	7.8e-05	0.000136	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.79e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	7.74e-05	0.000135	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.59e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	7.58e-05	0.000132	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.53e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	7.49e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	7.44e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—esophageal cancer	7.43e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—esophageal cancer	7.38e-05	0.000128	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPI1—esophageal cancer	7.24e-05	0.000126	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.24e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—esophageal cancer	7.22e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KDR—esophageal cancer	7.16e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	7.08e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	7.03e-05	0.000122	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	6.99e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—esophageal cancer	6.95e-05	0.000121	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.94e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	6.9e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	6.88e-05	0.00012	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.84e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	6.76e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	6.74e-05	0.000117	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.68e-05	0.000116	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.62e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	6.5e-05	0.000113	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.43e-05	0.000112	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—esophageal cancer	6.38e-05	0.000111	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNG7—esophageal cancer	6.3e-05	0.00011	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.26e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—esophageal cancer	6.22e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—esophageal cancer	6.14e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—esophageal cancer	6.12e-05	0.000107	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	6.11e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—esophageal cancer	6.1e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	6.01e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—esophageal cancer	5.97e-05	0.000104	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	5.94e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.9e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	5.9e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.87e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	5.86e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	5.77e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	5.74e-05	9.99e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—esophageal cancer	5.65e-05	9.84e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.63e-05	9.8e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.61e-05	9.77e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—esophageal cancer	5.61e-05	9.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.55e-05	9.66e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—esophageal cancer	5.49e-05	9.56e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	5.47e-05	9.53e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	5.31e-05	9.24e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO1—esophageal cancer	5.26e-05	9.15e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.26e-05	9.15e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	5.22e-05	9.08e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	5.21e-05	9.08e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSME1—esophageal cancer	5.18e-05	9.02e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSME2—esophageal cancer	5.18e-05	9.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	5.12e-05	8.91e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.99e-05	8.68e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—esophageal cancer	4.93e-05	8.58e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—esophageal cancer	4.89e-05	8.51e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—esophageal cancer	4.82e-05	8.39e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—esophageal cancer	4.79e-05	8.33e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—esophageal cancer	4.78e-05	8.32e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	4.75e-05	8.27e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—esophageal cancer	4.68e-05	8.15e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.63e-05	8.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	4.53e-05	7.88e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	4.52e-05	7.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.47e-05	7.78e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	4.45e-05	7.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	4.38e-05	7.62e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.2e-05	7.32e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	4.18e-05	7.28e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—esophageal cancer	4.16e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	4.15e-05	7.22e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CREBBP—esophageal cancer	4.09e-05	7.12e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	4.06e-05	7.07e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—esophageal cancer	4.05e-05	7.04e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—esophageal cancer	4.02e-05	6.99e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—esophageal cancer	3.93e-05	6.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	3.93e-05	6.84e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.84e-05	6.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	3.8e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.76e-05	6.55e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.68e-05	6.41e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—esophageal cancer	3.66e-05	6.38e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—esophageal cancer	3.63e-05	6.32e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—esophageal cancer	3.62e-05	6.29e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	3.55e-05	6.18e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.37e-05	5.87e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.35e-05	5.83e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—esophageal cancer	3.15e-05	5.48e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.08e-05	5.36e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	3.08e-05	5.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	3.08e-05	5.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—esophageal cancer	2.98e-05	5.19e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—esophageal cancer	2.79e-05	4.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.67e-05	4.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.59e-05	4.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—esophageal cancer	2.56e-05	4.46e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.46e-05	4.28e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.2e-05	3.84e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.06e-05	3.59e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.02e-05	3.51e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.9e-05	3.3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—esophageal cancer	1.68e-05	2.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.24e-05	2.16e-05	CbGpPWpGaD
